Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have been diagnosed with a primary brain tumour or a tumour at the base of the skull
- People whose tumour is suitable for a standard course of radiation therapy (using either conventional X-ray-based or proton-based radiation)
Who may not be able to join:
- People with certain tumour types that have poor expected outcomes, including: a specific type of brain tumour called IDH-wild-type glioma that was not fully removed by surgery; IDH-wild-type glioma that was fully removed but lacks a certain molecular marker (MGMT-promoter unmethylation); a Grade III meningioma; or a tumour known as H3K27M+ midline glioma
- People whose treatment requires radiation to the entire spine and brain, or to the entire ventricular system of the brain
- People whose radiation treatment plan uses larger-than-standard doses per session (a technique called hypofractionated or stereotactic radiation)
- People who are unable to complete written questionnaires or thinking and memory tests due to physical difficulties with movement or senses, or because they do not have sufficient proficiency in the Dutch language
- People who had an intellectual disability that was documented before their current diagnosis
- People with a pre-existing psychiatric condition that affects thinking or memory, such as psychosis, autism, or a learning disorder, diagnosed before the current brain tumour
- People whose tumour has come back (relapsed) and who have already been treated with chemotherapy and/or radiation therapy
- People with a genetic syndrome, such as Down syndrome
- People who are unable to undergo MRI scanning, for example due to severe claustrophobia or because they have certain metal implants in their body such as a pacemaker, implantable defibrillator (ICD), or neurostimulator
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maarten Lambrecht, MD PhD, UZ Leuven
Phone: 016 34 76 00
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of neurocognitive decline (changes in z-scores) compared to baseline at one year post-radiotherapy, for all cognitive domains (memory, executive functioning, attention and language); Development of a Normal Tissue Complication Probability model (NTCP-model) for each cognitive domain (memory, executive functioning, attention and language)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.